Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Libby MD

Peter Libby MD

Mallinckrodt Professor of Medicine, Harvard Medical School; Cardiovascular Specialist, Brigham and Women’s Hospital, Boston, Massachusetts

Dr. Peter Libby is a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and is the Mallinckrodt Professor of Medicine at Harvard Medical School in Boston. From 1998 through 2014, Dr. Libby served as the Chief of Cardiovascular Medicine at Brigham and Women’s Hospital. He holds honorary degrees from Harvard University in Cambridge, Massachusetts, from the University of Lille, France, from Laval University in Québec, and from J.W. Goethe Universität, Frankfurt am Main, Germany.

His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translating laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.

He has published extensively in medical journals, including Circulation and The New England Journal of Medicine, among others. He is also active in many organizations, including the American College of Cardiology and the American Heart Association, and was elected to the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists, where he served as President.

Disclosures

  • Consultant: Libby is an unpaid consultant to or is involved in clinical trials for: Amgen; AstraZeneca; Baim Institute; Beren Therapeutics; Esperion Therapeutics; Genentech; Kancera; Kowa Pharmaceuticals; Medimmune; Merck; Norvo Nordisk; Novartis; Pfizer; and Sanofi-Regeneron.
  • Advisory boards: Amgen; Caristo Diagnostics; Cartesian Therapeutics; CSL Behring; DalCor Pharmaceuticals; Dewpoint Therapeutics; Elucid Bioimaging; Kancera; Kowa Pharmaceuticals; Olatec Therapeutics; Medimmune; Novartis; PlaqueTec; TenSixteen Bio; Soley Therapeutics; XBiotech
  • Board of directors: XBiotech
  • Financial interest: Xbiotech; TenSixteen Bio; Soley Therapeutics
  • Research funding: Libby receives funding support from: National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, and 1R01HL163099-01); American Heart Association (18CSA34080399); RRM Charitable Fund; Simard Fund. Dr. Libby’s laboratory has received research funding from Novartis.

Dr. Libby’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.

Recent Contributions to PracticeUpdate:

  1. Rosuvastatin for Patients at Intermediate Risk for Cardiovascular Disease
  2. Another Crack in the HDL Edifice
  3. Triglyceride Level Is Associated With Mortality in Patients With Coronary Heart Disease
  4. Periodontitis Increases Risk of First Myocardial Infarction
  5. Effect of Evacetrapib on Cholesterol Efflux Capacity and Pre-Beta-1 HDL Levels
  6. Targeting LDL, Inflammation, or Both: Improving Outcomes With Precision
  7. Better Outcomes With Addition of Ezetimibe to Simvastatin
  8. Effect of Intensive Statin Therapy on Coronary High-Intensity Plaques
  9. Improved Production of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
  10. Ezetimibe Plus Statin Therapy After Acute Coronary Syndromes

Most Read This Week

Recently Updated